Evidence map›Paper›PMID 35416370›Full record

SynthesisReviews in medical virology2022

Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.

Samuel J Minkove, Junfeng Sun, Yan Li, Xizhong Cui, Diane Cooper, Peter Q Eichacker, Parizad Torabi-Parizi

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Reviews in medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Health influence of SARS-CoV-2 (COVID-19) on cancer: a review.Acta biochimica et biophysica Sinica · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Samuel J MinkoveCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Junfeng SunCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Yan LiCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Xizhong CuiCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Diane CooperNIH Library, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Peter Q EichackerCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Parizad Torabi-PariziCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-7446-1702
National Institutes of Health Clinical Center · USUnited States National Library of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetermining how prior immune checkpoint inhibitor (ICI) therapy influences outcomes in cancer patients presenting with COVID-19 is essential for patient management but must account for confounding variables.

methodsWe performed a systematic review and meta-analysis of studies reporting adjusted effects of ICIs on survival, severe events, or hospitalisation in cancer patients with COVID-19 based on variables including age, gender, diabetes mellitus, hypertension (HTN), chronic obstructive pulmonary disease, and other comorbidities. When adjusted effects were unavailable, unadjusted data were analysed.

resultsOf 42 observational studies (38 retrospective), 7 reported adjusted outcomes for ICIs and 2 provided sufficient individual patient data to calculate adjusted outcomes. In eight studies, adjusted outcomes were based on ≤7 variables. Over all studies, only one included >100 ICI patients while 26 included <10. ICIs did not alter the odds ratio (95%CI) (OR) of death significantly (random effects model), across adjusted (n = 8) [1.31 (0.58-2.95) p = 0.46; I

conclusionsAcross studies with adjusted and unadjusted results, ICIs did not alter outcomes significantly. But studies with comprehensive adjusted outcome data controlling for confounding variables are necessary to determine whether ICIs impact COVID-19 outcomes in cancer patients.

Indexed as

COVID-19 Drug TreatmentNeoplasmsHumansImmune Checkpoint InhibitorsRetrospective StudiesImmune Checkpoint InhibitorscancerCOVID-19immune checkpoint inhibitorsimmunotherapySARS-COV2d

Identifiers

PMID35416370
PMCPMC9111045
OpenAlexW4223646155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.